News headlines about Imprimis Pharmaceuticals (NASDAQ:IMMY) have trended somewhat positive on Tuesday, Accern Sentiment reports. The research group rates the sentiment of media coverage by monitoring more than twenty million news and blog sources. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. Imprimis Pharmaceuticals earned a media sentiment score of 0.11 on Accern’s scale. Accern also gave news stories about the specialty pharmaceutical company an impact score of 46.2897268343761 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the next several days.

Shares of Imprimis Pharmaceuticals (NASDAQ:IMMY) traded down $0.01 on Tuesday, hitting $1.57. 132,200 shares of the company’s stock traded hands, compared to its average volume of 310,032. Imprimis Pharmaceuticals has a one year low of $1.35 and a one year high of $4.69. The company has a quick ratio of 1.55, a current ratio of 1.88 and a debt-to-equity ratio of 1.68.

TRADEMARK VIOLATION NOTICE: This article was first published by Watch List News and is owned by of Watch List News. If you are accessing this article on another domain, it was illegally stolen and reposted in violation of international copyright law. The original version of this article can be read at

Imprimis Pharmaceuticals Company Profile

Imprimis Pharmaceuticals, Inc (Imprimis) is engaged in the development, production and dispensing of compounded pharmaceuticals. The Company operates through the business of developing drug therapies and providing such therapies through sterile and non-sterile pharmaceutical compounding services segment.

Insider Buying and Selling by Quarter for Imprimis Pharmaceuticals (NASDAQ:IMMY)

Receive News & Ratings for Imprimis Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Imprimis Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.